Literature DB >> 24900007

Assessment of Therapeutic Effect of Sunitinib by (11)C-Acetate PET Compared with FDG PET Imaging in a Patient with Metastatic Renal Cell Carcinoma.

Nobuyuki Oyama1, Noriko Takahara1, Yoko Hasegawa1, Kazuya Tanase1, Yoshiji Miwa1, Hironobu Akino1, Hidehiko Okazawa2, Takashi Kudo2, Yasuhisa Fujibayashi2, Osamu Yokoyama1.   

Abstract

Although sunitinib shows a high response rate in patients with untreated metastatic renal cell carcinoma (mRCC), quite a few patients show no therapeutic effect. Therefore, it is crucial to distinguish the patients who respond to sunitinib from those who do not as early as possible after the administration of the therapy. We herein report a case of mRCC in which (11)C-acetate (AC) positron emission tomography (PET) showed an early therapeutic effect of sunitinib treatment 4 weeks after its administration.

Entities:  

Keywords:  11C-acetate; Positron emission tomography; Renal cell carcinoma; Sunitinib; Therapeutic effect

Year:  2011        PMID： 24900007      PMCID： PMC4043014          DOI： 10.1007/s13139-011-0084-x

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN： 1869-3474


  11 in total

1.  Apoptosis and changes in glucose transport early after treatment of Morris hepatoma with gemcitabine.

Authors:  U Haberkorn; M E Bellemann; G Brix; H Kamencic; I Morr; U Traut; A Altmann; J Doll; J Blatter; R Kinscherf
Journal:  Eur J Nucl Med       Date:  2001-04

2.  Sunitinib in patients with metastatic renal cell carcinoma.

Authors:  Robert J Motzer; Brian I Rini; Ronald M Bukowski; Brendan D Curti; Daniel J George; Gary R Hudes; Bruce G Redman; Kim A Margolin; Jaime R Merchan; George Wilding; Michelle S Ginsberg; Jennifer Bacik; Sindy T Kim; Charles M Baum; M Dror Michaelson
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

3.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

4.  Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells.

Authors:  M Yoshimoto; A Waki; Y Yonekura; N Sadato; T Murata; N Omata; N Takahashi; M J Welch; Y Fujibayashi
Journal:  Nucl Med Biol       Date:  2001-02       Impact factor: 2.408

5.  Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer.

Authors:  Hideshi Miyakita; Masatosi Tokunaga; Hajime Onda; Yukio Usui; Hidechika Kinoshita; Nobuo Kawamura; Seiei Yasuda
Journal:  Int J Urol       Date:  2002-01       Impact factor: 3.369

6.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

Authors:  Haesun Choi; Chuslip Charnsangavej; Silvana C Faria; Homer A Macapinlac; Michael A Burgess; Shreyaskumar R Patel; Lei L Chen; Donald A Podoloff; Robert S Benjamin
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

7.  Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake.

Authors:  R Kubota; K Kubota; S Yamada; M Tada; T Ido; N Tamahashi
Journal:  J Nucl Med       Date:  1994-01       Impact factor: 10.057

8.  11C-Acetate PET imaging for renal cell carcinoma.

Authors:  Nobuyuki Oyama; Hidehiko Okazawa; Naoya Kusukawa; Taisei Kaneda; Yoshiji Miwa; Hironobu Akino; Yasuhisa Fujibayashi; Yoshiharu Yonekura; Michael J Welch; Osamu Yokoyama
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11-19       Impact factor: 9.236

9.  Carbon-11-acetate PET imaging in renal disease.

Authors:  P Shreve; P C Chiao; H D Humes; M Schwaiger; M D Gross
Journal:  J Nucl Med       Date:  1995-09       Impact factor: 10.057

10.  11C-acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma.

Authors:  Alessandra Maleddu; Maria A Pantaleo; Paolo Castellucci; Maria Astorino; Cristina Nanni; Margherita Nannini; Fiorenza Busato; Monica Di Battista; Mohsen Farsad; Filippo Lodi; Stefano Boschi; Stefano Fanti; Guido Biasco
Journal:  Tumori       Date:  2009 May-Jun
View more
  5 in total

Review 1.  Update on advances in molecular PET in urological oncology.

Authors:  Kazuhiro Kitajima; Shingo Yamamoto; Kazuhito Fukushima; Ryogo Minamimoto; Takao Kamai; Hossein Jadvar
Journal:  Jpn J Radiol       Date:  2016-05-24       Impact factor: 2.374

2.  Can Initial (18)F-FDG PET-CT Imaging Give Information on Metastasis in Patients with Primary Renal Cell Carcinoma?

Authors:  Haejun Lee; Kyung Hoon Hwang; Seog Gyun Kim; Geon Koh; Ji Hyun Kim
Journal:  Nucl Med Mol Imaging       Date:  2013-11-28

Review 3.  Role of positron emission tomography/computed tomography in the evaluation of renal cell carcinoma.

Authors:  Rahul Jena; Tushar Aditya Narain; Uday Pratap Singh; Aneesh Srivastava
Journal:  Indian J Urol       Date:  2021-04-01

Review 4.  PET-CT and PET-MR in urological cancers other than prostate cancer: An update on state of the art.

Authors:  Abdul Razik; Chandan Jyoti Das; Sanjay Sharma
Journal:  Indian J Urol       Date:  2018 Jan-Mar

Review 5.  Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation.

Authors:  Girolamo Ranieri; Ilaria Marech; Artor Niccoli Asabella; Alessandra Di Palo; Mariangela Porcelli; Valentina Lavelli; Giuseppe Rubini; Cristina Ferrari; Cosmo Damiano Gadaleta
Journal:  Int J Mol Sci       Date:  2017-09-09       Impact factor: 5.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.